Beta-testing of PI3-kinase inhibitors: is beta better?

Peter R Shepherd; William A Denny

doi:10.1158/2159-8290.CD-12-0122

Beta-testing of PI3-kinase inhibitors: is beta better?

Cancer Discov. 2012 May;2(5):393-4. doi: 10.1158/2159-8290.CD-12-0122.

Authors

Peter R Shepherd¹, William A Denny

Affiliation

¹ Department of Molecular Medicine and Pathology, School of Medical Sciences, University of Auckland, Auckland, New Zealand.

PMID: 22588874
DOI: 10.1158/2159-8290.CD-12-0122

Abstract

Although it has been known for some time that PTEN-null tumors require expression of the p110β isoform of phosphoinositide 3-kinase for growth, the corollary demonstration that small-molecule inhibitors of p110β are effective drugs for such tumors has not been shown. This has now been rectified by the demonstration that the TGX221 analogue KIN-193 is effective in mouse xenografts of HCC70 and PC3 human tumor cell lines.

Publication types

Comment

MeSH terms

Animals
Antineoplastic Agents / therapeutic use*
Enzyme Inhibitors / therapeutic use*
Female
Humans
Male
Neoplasms / drug therapy*
Phosphoinositide-3 Kinase Inhibitors*

Substances

Antineoplastic Agents
Enzyme Inhibitors
Phosphoinositide-3 Kinase Inhibitors